This HTML5 document contains 99 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00271/identifier/wikipedia/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00271/identifier/pharmgkb/
n20http://linked.opendata.cz/resource/AHFS/
n13http://linked.opendata.cz/resource/drugbank/company/
n10http://linked.opendata.cz/resource/mesh/concept/
n24http://linked.opendata.cz/resource/drugbank/dosage/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00271/identifier/pubchem-compound/
n21http://linked.opendata.cz/resource/drugbank/mixture/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00271/identifier/kegg-drug/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00271/identifier/pubchem-substance/
n23http://bio2rdf.org/drugbank:
n14http://linked.opendata.cz/resource/drugbank/drug/DB00271/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n7http://linked.opendata.cz/resource/drugbank/drug/DB00271/identifier/national-drug-code-directory/
n26http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/drugbank/medicinal-product/
n9http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00271/identifier/chemspider/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n25http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00271
rdf:type
n3:Drug
n3:description
A commonly used x-ray contrast medium. As diatrizoate meglumine and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography. [PubChem]
n3:dosage
n24:271B44B7-363D-11E5-9242-09173F13E4C5 n24:271B44B8-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:indication
Used, alone or in combination, for a wide variety of diagnostic imaging methods, including angiography, urography, cholangiography, computed tomography, hysterosalpingography, and retrograde pyelography. It can be used for imaging the gastrointestinal tract in patients allergic to barium.
n3:manufacturer
n13:271B44AC-363D-11E5-9242-09173F13E4C5 n13:271B44AD-363D-11E5-9242-09173F13E4C5 n13:271B44AA-363D-11E5-9242-09173F13E4C5 n13:271B44AB-363D-11E5-9242-09173F13E4C5 n13:271B44A8-363D-11E5-9242-09173F13E4C5 n13:271B44A9-363D-11E5-9242-09173F13E4C5
owl:sameAs
n23:DB00271 n26:DB00271
dcterms:title
Diatrizoate
adms:identifier
n6:46504704 n7:0407-0766-04 n8:2140 n11:D01013 n12:2055 n14:DB00271 n15:PA449281 n16:Diatrizoate
n3:mechanismOfAction
Diatrizoate is an iodine-containing X-ray contrast agent. Iodated contrast agents were among the first contrast agents developed. Iodine is known to be particular electron-dense and to effectively scatter or stop X-rays. A good contrast agent requires a high density of electron-dense atoms. Therefore, the more iodine, the more "dense" the x-ray effect. Iodine based contrast media are water soluble and harmless to the body. These contrast agents are sold as clear colorless water solutions, the concentration is usually expressed as mg I/ml. Modern iodinated contrast agents can be used almost anywhere in the body. Most often they are used intravenously, but for various purposes they can also be used intraarterially, intrathecally (the spine) and intraabdominally - just about any body cavity or potential space.
n3:packager
n13:271B44A2-363D-11E5-9242-09173F13E4C5 n13:271B44A3-363D-11E5-9242-09173F13E4C5 n13:271B44A0-363D-11E5-9242-09173F13E4C5 n13:271B44A1-363D-11E5-9242-09173F13E4C5 n13:271B44A6-363D-11E5-9242-09173F13E4C5 n13:271B44A7-363D-11E5-9242-09173F13E4C5 n13:271B44A4-363D-11E5-9242-09173F13E4C5 n13:271B44A5-363D-11E5-9242-09173F13E4C5 n13:271B449E-363D-11E5-9242-09173F13E4C5 n13:271B449F-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
However, it is not metabolized but excreted unchanged in the urine, each diatrizoate molecule remaining "obligated" to its sodium moiety. The liver and small intestine provide the major alternate route of excretion for diatrizoate. Injectable radiopaque diagnostic agents are excreted unchanged in human milk. Saliva is a minor secretory pathway for injectable radiopaque diagnostic agents.
n3:synonym
Acidum diacetylaminotrijodbenzoicum Triombrin Acidum amidotrizoicum Urogranoic acid Amidotrizoate Diatrizoic acid (anhydrous) Amidotrizoic acid (anhydrous) Acide amidotrizoique Urografin acid Diatrizoesaure 3,5-Bis(acetylamino)-2,4,6-triiodobenzoic acid Diatrizoate Amidotrizoic Acid 3,5-diacetamido-2,4,6-triiodobenzoic acid 2,4,6-Triiodo-3,5-diacetamidobenzoic acid Methalamic acid Diatrizoic acid
n3:toxicity
High osmolal radiocontrast agents like diatrizoate are cytotoxic to renal cells. The toxic effects include apoptosis, cellular energy failure, disruption of calcium homeostasis, and disturbance of tubular cell polarity, and are thought to be linked to oxidative stress.
n19:hasAHFSCode
n20:36-68-00
n3:mixture
n21:271B449D-363D-11E5-9242-09173F13E4C5
n3:salt
n3:synthesisReference
Larsen, A.A.; US. Patent 3,076,024; January 29, 1963; assigned to Sterling Drug,Inc.
n9:hasConcept
n10:M0006219
n3:IUPAC-Name
n4:271B44BD-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B44C3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B44C2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B44BF-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B44C0-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B44C1-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B44BB-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B44D4-363D-11E5-9242-09173F13E4C5 n4:271B44B9-363D-11E5-9242-09173F13E4C5 n4:271B44BC-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B44BA-363D-11E5-9242-09173F13E4C5
n19:hasATCCode
n25:V08AA01
n3:H-Bond-Acceptor-Count
n4:271B44C9-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B44CA-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B44C4-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B44C5-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B44C7-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B44C6-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B44C8-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
117-96-4
n3:category
n3:containedIn
n18:271B44B6-363D-11E5-9242-09173F13E4C5 n18:271B44B0-363D-11E5-9242-09173F13E4C5 n18:271B44B1-363D-11E5-9242-09173F13E4C5 n18:271B44AE-363D-11E5-9242-09173F13E4C5 n18:271B44AF-363D-11E5-9242-09173F13E4C5 n18:271B44B4-363D-11E5-9242-09173F13E4C5 n18:271B44B5-363D-11E5-9242-09173F13E4C5 n18:271B44B2-363D-11E5-9242-09173F13E4C5 n18:271B44B3-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B44CF-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B44D1-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B44D2-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B44D3-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B44CE-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B44CD-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B44D0-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B44BE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B44CB-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B44CC-363D-11E5-9242-09173F13E4C5